For the immunocompromised, a preventive drug offers something vaccines cannot
In a moment that acknowledges the uneven terrain of immunity, Brazil's health authority unanimously extended a new form of protection to those for whom vaccines alone cannot offer sufficient shelter. Evusheld, a dual monoclonal antibody developed by AstraZeneca, received emergency approval on Thursday as a preventive measure for immunocompromised Brazilians aged 12 and older — organ transplant recipients, those living with advanced HIV, patients in leukemia treatment, and others whose bodies cannot reliably answer the call of vaccination. The decision does not diminish the role of vaccines; rather, it fills a gap that medicine has long struggled to address — the space between vulnerability and defense.
- Immunocompromised patients have remained dangerously exposed throughout the pandemic, as their bodies often fail to mount adequate responses even after vaccination.
- Anvisa's unanimous vote signals institutional urgency — seven COVID medications have now been cleared, even as one monoclonal antibody was recently revoked for failing to prove efficacy against omicron.
- The approval draws a firm line: Evusheld is a complement to vaccination, not a replacement, and must be administered at least two weeks after eligible patients receive their vaccine doses.
- Brazil's Health Ministry has entered acquisition talks with AstraZeneca, moving quickly to translate regulatory approval into real supply for the country's most vulnerable populations.
- Patients receiving the drug are still required to maintain masks, isolation protocols, and hygiene practices — protection layered upon protection, not a signal that the threat has passed.
On a Thursday in February, Brazil's health regulator Anvisa gave unanimous approval to Evusheld — a combination of two monoclonal antibodies, cilgavimab and tixagevimab, made by AstraZeneca — for emergency use as a COVID-19 preventive in patients who have not yet been exposed to the virus. The drug is aimed at people 12 and older with moderately to severely compromised immune systems: organ transplant recipients, those with severe primary immunodeficiency disorders, leukemia patients, people with advanced or untreated HIV, and individuals who cannot receive vaccines due to documented severe allergic reactions.
Anvisa's board was careful to frame the approval as an addition to vaccination strategies, not a substitute. For patients who can safely be vaccinated, Evusheld must be given at least two weeks after their doses. The regulator stressed that the drug exists for a specific population — those whose bodies cannot mount an adequate immune response even with immunization.
Director Meiruze Sousa Freitas, who presented the case, described the approval as a direct response to the elevated risk of hospitalization and death that immunocompromised patients continue to face. She also cautioned that recipients must maintain standard precautions: masks, appropriate isolation, and frequent hand hygiene. AstraZeneca had announced in November that the drug reduced both infection risk and the likelihood of severe disease or death, and the company has already begun supply discussions with Brazil's Health Ministry.
The approval arrives as Anvisa has now cleared seven COVID-19 medications in total, though it recently revoked authorization for another monoclonal antibody combination after the manufacturer failed to demonstrate effectiveness against the omicron variant. Evusheld's clearance represents a quiet but significant acknowledgment: that protection, like vulnerability, is not distributed equally, and that a health system's reach must extend to those the standard tools cannot fully cover.
Brazil's health regulator gave its unanimous blessing on Thursday to Evusheld, a new drug designed to prevent COVID-19 in people whose immune systems cannot reliably fight off infection. The Anvisa board approved the medication—a combination of two monoclonal antibodies called cilgavimab and tixagevimab, developed by AstraZeneca—for emergency use as a preventive measure in patients who have not yet been exposed to the virus.
The drug is intended for people aged 12 and older whose immune systems are moderately to severely compromised. This includes organ transplant recipients, those with severe primary immunodeficiency disorders like DiGeorge syndrome, patients undergoing leukemia treatment, and people with advanced or untreated HIV infection. It can also be given to individuals who cannot receive COVID-19 vaccines due to a documented history of severe allergic reactions. For those who can be vaccinated, however, Evusheld is not a substitute. If a patient is eligible for vaccination, the drug must be administered at least two weeks after their vaccine doses.
The distinction matters. Anvisa's board emphasized that this approval is meant to complement vaccination strategies, not replace them. One regulator stressed that for patients who can safely receive vaccines, the drug should work alongside immunization, not instead of it. The agency made clear that Evusheld is an additional tool for a specific population—those whose bodies cannot mount an adequate immune response even with vaccination.
Meiruze Sousa Freitas, the Anvisa director who presented the case, framed the approval as a response to the pandemic's ongoing threat to the most vulnerable. For people with leukemia, primary immunodeficiency, acquired immunodeficiency, or those taking immunosuppressive medications—including transplant recipients—the risk of hospitalization and death from COVID-19 remains elevated. A preventive drug offers them a layer of protection that vaccination alone cannot provide. Freitas cautioned, though, that patients receiving Evusheld must continue standard precautions: wearing masks, maintaining isolation when appropriate, avoiding shared personal items, and practicing frequent hand hygiene.
AstraZeneca announced in November that its monoclonal antibody reduced the risk of COVID-19 infection and also lowered the chances of developing severe disease or death. The company has already begun discussions with Brazil's Health Ministry about supplying the drug to the country. This approval comes as Anvisa has now cleared seven COVID-19 medications overall, though the agency recently revoked emergency authorization for another monoclonal antibody combination—ballanivimab and etesevimab—after the company failed to provide evidence of its effectiveness against the omicron variant.
Evusheld represents a recognition that vaccination, while crucial, does not work equally for everyone. For the immunocompromised, a preventive drug offers something vaccines cannot: a direct defense before infection takes hold. The approval signals that Brazil's health system is preparing to offer this option to those who need it most.
Citações Notáveis
Pre-exposure prophylaxis with Evusheld does not replace vaccination in individuals for whom COVID-19 vaccination is recommended— Anvisa regulator (paraphrased)
Pre-exposure prophylaxis can be an important weapon to combat severe illness in vulnerable populations at risk of hospitalization and death, including those with leukemia, primary or acquired immunodeficiency, or those undergoing immunosuppressive treatment— Meiruze Sousa Freitas, Anvisa director (paraphrased)
A Conversa do Hearth Outra perspectiva sobre a história
Why does this drug matter if we already have vaccines?
Because vaccines don't work well for people whose immune systems are broken—transplant patients, people with HIV, those on immunosuppressive drugs. Their bodies can't mount the response a vaccine requires. This drug gives them actual protection.
So it's a replacement for vaccination?
No, that's the crucial part. For people who can be vaccinated, this is additional protection, not a substitute. You get vaccinated, wait two weeks, then get the drug. It's layering defenses.
Who exactly gets this?
People 12 and up with moderate to severe immune compromise. Organ transplant recipients, people with primary immunodeficiency, leukemia patients, people with advanced untreated HIV. Also anyone who had a severe allergic reaction to a vaccine.
How does it actually work?
It's two monoclonal antibodies—cilgavimab and tixagevimab. Think of them as ready-made immune soldiers you inject before exposure. They're already there waiting if the virus shows up.
Did the regulator have any concerns?
They emphasized it's not a vaccine replacement and that patients still need masks, isolation, hygiene. It's one tool in a toolkit, not a magic shield.
What happens next?
Brazil's Health Ministry is already talking to AstraZeneca about buying it. The question now is how quickly they can get it to the patients who need it.